Phase I-II trial of intramuscularly administered bleomycin.

摘要: Abstract Bleomycin was administered intramuscularly on one of four schedules in a phase I–II trial conducted by the Eastern Cooperative Oncology Group. A total 168 evaluable patients received either bleomycin 5 mg/m 2 daily, weekly, 20 weekly or 40 weekly. The latter dose proved to be toxic and discontinued. Comparable toxicity seen with other three schedules. qualitatively quantitatively similar that reported doses, routes administration except no radiographic evidence pulmonary seen. Patients hematologic malignancies solid tumors responded equally well low high highest response rates were testicular lymphomas. median duration 1–2 months.